Given the potential for recurrent vasculitis with either pegylated or nonpegylated G-CSF, as well as patient's general chemotherapy tolerance to date, our patient's ddAC was switched to every three weeks of dosing so that growth factor support was no longer preemptively required; her symptoms did not recur. The gene discussed is CSF3; the disease is vasculitis.